Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators hypothesize that chronic heart failure is associated with a general stem cell dysfunction, which translates into reduced paracrine function of adult stem cells from patients with chronic heart failure as compared to patients with preserved systolic function.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non heart failure patients | Patients without heart failure undergoing open chest surgery |
| |
| Orthopedic patients | Patients without heart failure undergoing orthopedic surgery |
| |
| Heart failure patients | Patients with heart failure undergoing open chest surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surgery | Other | Patients undergoing surgery for either cardiac surgery or orthopedic surgery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Paracrine properties of bone marrow cells from patients with heart failure | To compare the paracrine properties of bone marrow-derived stem cells harvested from patients suffering chronic heart failure vs healthy subjects. In particular, we aim to determine if the cytoprotective, pro-angiogenic and anti-fibrotic effects mediated by bone marrow stem cells of heart failure patients are similar to those from healthy patients. | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| To study preconditioning of different bone marrow stem cells with different cytokines | 1 day | |
| To study in detail the temporal and spatial expression of paracrine factors in bone marrow stem cells in vitro, and to study the differences between bone marrow stem cells from patients with and without chronic heart failure |
Not provided
Inclusion Criteria:
For all participants:
Before any study-specific procedures, the appropriate written informed consent must be obtained.
Male and female older than 18 years of age.
For the cardiac patients:
Being accepted for cardiothoracic surgery with the use of open chest surgery
A known left ventricular ejection fraction, either assessed by echocardiography, MUGA or MRI. If LVEF <40% a subject will be assigned to the chronic heart failure group, if LVEF >40% a subject will be assigned to the control group.
For the non-cardiac patients:
Accepted for orthopedic surgery (e.g. total hip replacement) at the department of orthopedic surgery.
Exclusion Criteria:
An unstable medical condition, defined as having been hospitalized for a non-cardiac condition within 4 weeks of screening, or otherwise unstable in the judgment of the investigator (e.g. at risk of complications or adverse events unrelated to study participation).
Younger than 18 years of age.
Clinical history of chronic kidney disease (at any point prior to registration).
Any known hepatic disease.
Recent (within 3 months) history of alcohol or illicit drug abuse disorder, based on self-report.
Clinically significant abnormality in chemistry, hematology, or urinalysis parameters performed within the screening period.
Participation in any investigational device or drug trial(s) or receiving investigational agent(s) within 30 days.
Any condition (e.g. psychiatric illness, etc.) or situation that, in the investigator's opinion, could put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
Legally incompetent adults, for which reason what so ever.
For the non-cardiac patients:
A known history of cardiovascular disease.
Not provided
Not provided
Not provided
Man and woman, undergoing cardiothoracic surgery, older than 18 years of age, with and without preserved left ventricular ejection fraction (LVEF <40% and >40%). Controls are man and women, older than 18 years of age, scheduled for orthopaedic surgery without a history of cardiac disease.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| W. T. Ruifrok, MD | Contact | +31 50 361 61 61 | 10248 | w.t.ruifrok@thorax.umcg.nl |
| R. A. de Boer, MD, PhD | Contact | +31 50 361 61 61 | 15381 | r.a.de.boer@thorax.umcg.nl |
| Name | Affiliation | Role |
|---|---|---|
| W. T. Ruifrok, MD | University Medical Center Groningen | Principal Investigator |
| R. A. de Boer, MD, PhD | University Medical Center Groningen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Heart, Blood and Lung , University of Pavia | Pavia | Italy |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood, serum, white cells, urine, bone marrow
| 1 day |
| To evaluate potential molecular mechanisms involved | 1 day |
| To find mechanisms to enhance expansion of different bone marrow stem cells in vitro | 1 day |
| W. H. van Gilst, PhD |
| University Medical Center Groningen |
| Study Chair |
| M. Gnecchi, MD, PhD | University of Pavia | Study Director |
| L. Kleijn, MD | University Medical Center Groningen | Principal Investigator |
| University Medical Center Groningen | Groningen | Provincie Groningen | 9700 RB | Netherlands |
|